Stock listing

NASDAQ:BIAF bioAffinity Technologies, Inc. Stock

Home listing (NASDAQ) of bioAffinity Technologies, Inc.

Follow bioAffinity Technologies, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:BIAF

$3.73 USD -0.23 (-5.8%)

Close on Oct 16, 2026

bioAffinity Technologies, Inc. logo
Ticker
NASDAQ:BIAF
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Bioaffinity Technologies (NASDAQ:BIAF) Q4 2022 Earnings Call

    Mon, Apr 03, 2023 · 9:00 AM ET

    Watch Transcript

  • Bioaffinity Technologies (NASDAQ:BIAF) Q3 2022 Earnings Call

    Mon, Nov 14, 2022 · 8:00 AM ET

    Watch Transcript

Latest news

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

Oct 15, 2026

bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026

Oct 13, 2026

BioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 9, 2026

bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm

Oct 8, 2026

bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026

Oct 6, 2026

BioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL

Sep 30, 2026

BioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference

Sep 22, 2026

BioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath(R) Lung Noninvasive Lung Cancer Diagnostic

Sep 18, 2026

BioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic

Sep 17, 2026

BioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

Sep 9, 2026

All bioAffinity Technologies, Inc. news

Financings

  • Registered direct offering of common stock (or pre-funded warrants in lieu thereof)

    Oct 9, 2026

    Closed: US$4M raised · US$6.122 a share · WallachBeth Capital, LLC

    Dealers: WallachBeth Capital, LLC (lead)

    Buyers: institutional investor

    Use of proceeds: Working capital, supporting expected growing sales for CyPath Lung, and general corporate purposes

    Announced Oct 8, 2026 · Closed Oct 9, 2026

  • Private placement of warrants to purchase common stock

    Oct 9, 2026

    Closed: Warrants at US$6.122 for 60 months

    Announced Oct 8, 2026 · Closed Oct 9, 2026

  • Private placement of pre-funded warrants with accompanying warrants

    Aug 17, 2026

    Closed: US$4M raised · US$0.4657 a share · Warrants at US$0.4727 for 60 months · WallachBeth Capital LLC

    Dealers: WallachBeth Capital LLC (lead)

    Announced Aug 13, 2026 · Closed Aug 17, 2026

Read by 6ix AI from the company's releases

Decks

bioAffinity Technologies, Inc. on 6ix

News releases
52 in the last 12 months · 132 in all · newest Oct 15, 2026 · oldest 2022
Calls
2 calls with a replay · 2 with a transcript · latest Apr 3, 2023
Decks
6 decks · latest Sep 11, 2026

Where bioAffinity Technologies, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BIAF · Home listing · This pageNASDAQUnited StatesUSD
BOATS:BIAFBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about bioAffinity Technologies, Inc.